Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $282.0 million.

  • Mirum Pharmaceuticals' Cash & Equivalents rose 2648.44% to $282.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.0 million, marking a year-over-year increase of 2648.44%. This contributed to the annual value of $222.5 million for FY2024, which is 2229.03% down from last year.
  • Mirum Pharmaceuticals' Cash & Equivalents amounted to $282.0 million in Q3 2025, which was up 2648.44% from $228.1 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Cash & Equivalents high stood at $303.1 million for Q3 2023, and its period low was $49.4 million during Q1 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' median Cash & Equivalents value was $228.1 million (recorded in 2025), while the average stood at $220.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 7940.02% in 2023, then surged by 51280.68% in 2024.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Cash & Equivalents stood at $131.3 million in 2021, then dropped by 2.54% to $128.0 million in 2022, then soared by 123.69% to $286.3 million in 2023, then decreased by 22.29% to $222.5 million in 2024, then rose by 26.75% to $282.0 million in 2025.
  • Its last three reported values are $282.0 million in Q3 2025, $228.1 million for Q2 2025, and $211.8 million during Q1 2025.